Skip to content
2000
image of Assessment Value of Electromyography for Bortezomib-Related Peripheral Neuropathy

Abstract

Introduction

This study investigates the relationship between National Cancer Institute Common Terminology Criteria (NCI-CTC) for grading bortezomib-induced peripheral neuropathy (BIPN) and objective motor/sensory nerve dysfunctions assessed by nerve conduction studies (NCS). It also evaluates the correlation between specific nerve conduction abnormalities and progression-free survival (PFS).

Methods

Thirty-three patients with multiple myeloma developing peripheral neuropathy during bortezomib treatment were enrolled. Participants were grouped based on NCI-CTC toxicity scores (< 2, n=17; ≥ 2, n=16). Comprehensive NCS were performed, assessing compound muscle action potentials (CMAP), motor conduction velocities (MCV), sensory nerve action potentials (SNAP), and sensory conduction velocities (SCV) across ulnar, median, tibial, peroneal, sural, and superficial peroneal nerves. Correlation analyses were used to examine the association between NCS parameters and PFS.

Results

Patients with higher NCI-CTC grades (≥ 2) exhibited significant reductions in motor and sensory nerve conduction parameters. Notably, the peroneal nerve showed significant decreases in CMAP (0.0059) and MCV (0.0223). The superficial peroneal nerve displayed a significant reduction in SCV (0.0189). A strong positive correlation was found between median nerve SNAP and longer PFS (r=0.558, 0.001).

Discussion

The findings indicate that higher clinical grades of BIPN (NCI-CTC ≥ 2) are associated with objective neurophysiological evidence of worsened nerve function, with the peroneal nerve being particularly affected. The correlation between median nerve SNAP and PFS suggests that NCS parameters could potentially serve as prognostic markers in patients with BIPN.

Conclusion

Bortezomib-induced neurotoxicity leads to significant impairments in both motor and sensory nerve conduction. Median nerve SNAP shows promise as a predictor for PFS, underscoring the potential value of NCS in monitoring neurotoxicity and guiding clinical management in patients receiving bortezomib.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cn/10.2174/011570159X376896250624070328
2025-07-09
2025-09-13

  • From This Site

    /content/journals/cn/10.2174/011570159X376896250624070328
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Kyle R.A. Rajkumar S.V. Multiple myeloma. Blood 2008 111 6 2962 2972 10.1182/blood‑2007‑10‑078022 18332230
    [Google Scholar]
  2. Palumbo A. Anderson K. Multiple myeloma. N. Engl. J. Med. 2011 364 11 1046 1060 10.1056/NEJMra1011442 21410373
    [Google Scholar]
  3. Mateos M.V. San Miguel J.F. How should we treat newly diagnosed multiple myeloma patients? Hematology 2013 2013 1 488 495 10.1182/asheducation‑2013.1.488 24319223
    [Google Scholar]
  4. Richardson P.G. Anderson K.C. Bortezomib: A novel therapy approved for multiple myeloma. Clin. Adv. Hematol. Oncol. 2003 1 10 596 600 16258456
    [Google Scholar]
  5. Łuczkowska K. Rogińska D. Kulig P. Bielikowicz A. Baumert B. Machaliński B. Bortezomib-induced epigenetic alterations in nerve cells: Focus on the mechanisms contributing to the peripheral neuropathy development. Int. J. Mol. Sci. 2022 23 5 2431 10.3390/ijms23052431 35269574
    [Google Scholar]
  6. Gupta P. Goel L. Pahuja M. Mechanistic involvement of inflammation in bortezomib-induced peripheral neuropathy. Comb. Chem. High Throughput Screen. 2022 25 10 1595 1600 10.2174/1386207325666220524144147 35611787
    [Google Scholar]
  7. Yan W Wu Z Zhang Y The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy. Biomed. Pharmacother. 2021 142 112068 10.1016/j.biopha.2021.112068
    [Google Scholar]
  8. Yamamoto S. Egashira N. Pathological mechanisms of bortezomib-induced peripheral neuropathy. Int. J. Mol. Sci. 2021 22 2 888 10.3390/ijms22020888 33477371
    [Google Scholar]
  9. Argyriou A.A. Iconomou G. Kalofonos H.P. Bortezomib-induced peripheral neuropathy in multiple myeloma: A comprehensive review of the literature. Blood 2008 112 5 1593 1599 10.1182/blood‑2008‑04‑149385 18574024
    [Google Scholar]
  10. Argyriou A.A. Cavaletti G. Bruna J. Kyritsis A.P. Kalofonos H.P. Bortezomib-induced peripheral neurotoxicity: An update. Arch. Toxicol. 2014 88 9 1669 1679 10.1007/s00204‑014‑1316‑5 25069804
    [Google Scholar]
  11. Bechakra M. Nieuwenhoff M.D. van Rosmalen J. Groeneveld G.J. Scheltens-de Boer M. Sonneveld P. van Doorn P.A. de Zeeuw C.I. Jongen J.L.M. Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain. Mol. Pain 2018 14 1744806918797042 10.1177/1744806918797042 30152246
    [Google Scholar]
  12. Li T Mizrahi D Goldstein D Chemotherapy and peripheral neuropathy. Neurol. Sci. 2021 42 10 4109 4121 10.1007/s10072‑021‑05576‑6
    [Google Scholar]
  13. Flatters S.J.L. Dougherty P.M. Colvin L.A. Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): A narrative review. Br. J. Anaesth. 2017 119 4 737 749 10.1093/bja/aex229 29121279
    [Google Scholar]
  14. Rampen A.J. Jongen J.L. van Heuvel I. Scheltens-de Boer M. Sonneveld P. van den Bent M.J. Bortezomib-induced polyneuropathy. Neth. J. Med. 2013 71 3 128 133 23712808
    [Google Scholar]
  15. Yang Y. Zhao B. Lan H. Sun J. Wei G. Bortezomib-induced peripheral neuropathy: Clinical features, molecular basis, and therapeutic approach. Crit. Rev. Oncol. Hematol. 2024 197 104353 10.1016/j.critrevonc.2024.104353 38615869
    [Google Scholar]
  16. Durie B.G.M. Hoering A. Abidi M.H. Rajkumar S.V. Epstein J. Kahanic S.P. Thakuri M. Reu F. Reynolds C.M. Sexton R. Orlowski R.Z. Barlogie B. Dispenzieri A. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial. Lancet 2017 389 10068 519 527 10.1016/S0140‑6736(16)31594‑X 28017406
    [Google Scholar]
  17. Moreau P. Hulin C. Macro M. Caillot D. Chaleteix C. Roussel M. Garderet L. Royer B. Brechignac S. Tiab M. Puyade M. Escoffre M. Stoppa A.M. Facon T. Pegourie B. Chaoui D. Jaccard A. Slama B. Marit G. Laribi K. Godmer P. Luycx O. Eisenmann J.C. Allangba O. Dib M. Araujo C. Fontan J. Belhadj K. Wetterwald M. Dorvaux V. Fermand J.P. Rodon P. Kolb B. Glaisner S. Malfuson J.V. Lenain P. Biron L. Planche L. Caillon H. Avet-Loiseau H. Dejoie T. Attal M. VTD is superior to VCD prior to intensive therapy in multiple myeloma: Results of the prospective IFM2013-04 trial. Blood 2016 127 21 2569 2574 10.1182/blood‑2016‑01‑693580 27002117
    [Google Scholar]
  18. Sonneveld P. Dimopoulos M.A. Boccadoro M. Quach H. Ho P.J. Beksac M. Hulin C. Antonioli E. Leleu X. Mangiacavalli S. Perrot A. Cavo M. Belotti A. Broijl A. Gay F. Mina R. Nijhof I.S. van de Donk N.W.C.J. Katodritou E. Schjesvold F. Sureda Balari A. Rosiñol L. Delforge M. Roeloffzen W. Silzle T. Vangsted A. Einsele H. Spencer A. Hajek R. Jurczyszyn A. Lonergan S. Ahmadi T. Liu Y. Wang J. Vieyra D. van Brummelen E.M.J. Vanquickelberghe V. Sitthi-Amorn A. de Boer C.J. Carson R. Rodriguez-Otero P. Bladé J. Moreau P. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 2024 390 4 301 313 10.1056/NEJMoa2312054 38084760
    [Google Scholar]
  19. Velasco R. Alberti P. Bruna J. Psimaras D. Argyriou A.A. Bortezomib and other proteosome inhibitors—induced peripheral neurotoxicity: From pathogenesis to treatment. J. Peripher. Nerv. Syst. 2019 24 S2 Suppl. 2 S52 S62 10.1111/jns.12338 31647153
    [Google Scholar]
  20. Argyriou A.A. Bruna J. Genazzani A.A. Cavaletti G. Chemotherapy-induced peripheral neurotoxicity: Management informed by pharmacogenetics. Nat. Rev. Neurol. 2017 13 8 492 504 10.1038/nrneurol.2017.88 28664909
    [Google Scholar]
  21. Pancheri E. Guglielmi V. Wilczynski G.M. Malatesta M. Tonin P. Tomelleri G. Nowis D. Vattemi G. Non-hematologic toxicity of bortezomib in multiple myeloma: The neuromuscular and cardiovascular adverse effects. Cancers 2020 12 9 2540 10.3390/cancers12092540 32906684
    [Google Scholar]
  22. Selvy M. Kerckhove N. Pereira B. Barreau F. Nguyen D. Busserolles J. Giraudet F. Cabrespine A. Chaleteix C. Soubrier M. Bay J.O. Lemal R. Balayssac D. Prevalence of chemotherapy-induced peripheral neuropathy in multiple myeloma patients and its impact on quality of life: A single center cross-sectional study. Front. Pharmacol. 2021 12 637593 10.3389/fphar.2021.637593 33967771
    [Google Scholar]
  23. Luczkowska K. Litwinska Z. Paczkowska E. Machalinski B. Pathophysiology of drug-induce peripheral neuropathy in patients with multiple myeloma. J. Physiol. Pharmacol. 2018 69 2 10.26402/jpp.2018.2.02 29920472
    [Google Scholar]
  24. Singh M. Thomas V.M. Mulay S. Bortezomib-induced motor neuropathy: A case report. J. Oncol. Pharm. Pract. 2020 26 6 1549 1552 10.1177/1078155220904153 32054409
    [Google Scholar]
  25. Vaxman I. Mauerman M.L. Gatt M.L. Berger T. Gertz M.A. Foot drop in patients treated with bortezomib – a case series and review of the literature. Leuk. Lymphoma 2022 63 3 722 728 10.1080/10428194.2021.1992758 34702127
    [Google Scholar]
  26. Loprinzi C.L. Lacchetti C. Bleeker J. Cavaletti G. Chauhan C. Hertz D.L. Kelley M.R. Lavino A. Lustberg M.B. Paice J.A. Schneider B.P. Lavoie Smith E.M. Smith M.L. Smith T.J. Wagner-Johnston N. Hershman D.L. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J. Clin. Oncol. 2020 38 28 3325 3348 10.1200/JCO.20.01399 32663120
    [Google Scholar]
  27. Kandula T. Farrar M.A. Kiernan M.C. Krishnan A.V. Goldstein D. Horvath L. Grimison P. Boyle F. Baron-Hay S. Park S.B. Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. Clin. Neurophysiol. 2017 128 7 1166 1175 10.1016/j.clinph.2017.04.009 28511129
    [Google Scholar]
  28. Park S.B. Alberti P. Kolb N.A. Gewandter J.S. Schenone A. Argyriou A.A. Overview and critical revision of clinical assessment tools in chemotherapy‐induced peripheral neurotoxicity. J. Peripher. Nerv. Syst. 2019 24 S2 S13 S25 10.1111/jns.12333 31647154
    [Google Scholar]
  29. Bechakra M. Nieuwenhoff M.D. Rosmalen J.V. Groeneveld G.J. J P M Huygen F. Zeeuw C.I. Doorn P.A.V. Jongen J.L.M. Pain-related changes in cutaneous innervation of patients suffering from bortezomib-induced, diabetic or chronic idiopathic axonal polyneuropathy. Brain Res. 2020 1730 146621 10.1016/j.brainres.2019.146621 31926911
    [Google Scholar]
  30. Allegra A. Rizzo V. Innao V. Alibrandi A. Mazzeo A. Leanza R. Terranova C. Gentile L. Girlanda P. Allegra A. Alonci A. Musolino C. Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: A study on 18 patients with multiple myeloma. Arch. Med. Sci. 2021 18 3 696 703 10.5114/aoms/114269 35591819
    [Google Scholar]
  31. Cavaletti G. Frigeni B. Lanzani F. Piatti M. Rota S. Briani C. Zara G. Plasmati R. Pastorelli F. Caraceni A. Pace A. Manicone M. Lissoni A. Colombo N. Bianchi G. Zanna C. The total neuropathy score as an assessment tool for grading the course of chemotherapy‐induced peripheral neurotoxicity: Comparison with the national cancer institute‐common toxicity scale. J. Peripher. Nerv. Syst. 2007 12 3 210 215 10.1111/j.1529‑8027.2007.00141.x 17868248
    [Google Scholar]
  32. Cavaletti G. Frigeni B. Lanzani F. Mattavelli L. Susani E. Alberti P. Cortinovis D. Bidoli P. Chemotherapy-induced peripheral neurotoxicity assessment: A critical revision of the currently available tools. Eur. J. Cancer 2010 46 3 479 494 10.1016/j.ejca.2009.12.008 20045310
    [Google Scholar]
  33. Richardson P.G. Xie W. Mitsiades C. Chanan-Khan A.A. Lonial S. Hassoun H. Avigan D.E. Oaklander A.L. Kuter D.J. Wen P.Y. Kesari S. Briemberg H.R. Schlossman R.L. Munshi N.C. Heffner L.T. Doss D. Esseltine D.L. Weller E. Anderson K.C. Amato A.A. Single-agent bortezomib in previously untreated multiple myeloma: Efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J. Clin. Oncol. 2009 27 21 3518 3525 10.1200/JCO.2008.18.3087 19528374
    [Google Scholar]
  34. Zhang Y. Zhang H. Wang J. Wei X. Qu Y. Xu F. Zhang L. A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients. Oncol. Res. 2024 32 5 955 963 10.32604/or.2023.043922 38686049
    [Google Scholar]
  35. Dong M. Zhang J. Han X. He J. Zheng G. Cai Z. Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients. Sci. Rep. 2022 12 1 10061 10.1038/s41598‑022‑13935‑2 35710565
    [Google Scholar]
  36. Morawska M. Grzasko N. Kostyra M. Wojciechowicz J. Hus M. Therapy‐related peripheral neuropathy in multiple myeloma patients. Hematol. Oncol. 2015 33 4 113 119 10.1002/hon.2149 25399783
    [Google Scholar]
  37. Beijers A.J.M. Oerlemans S. Mols F. Eurelings M. Minnema M.C. Vreugdenhil A. van de Poll-Franse L.V. The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: Results from the population-based PROFILES registry. Ann. Hematol. 2017 96 4 653 663 10.1007/s00277‑017‑2927‑8 28116479
    [Google Scholar]
  38. Lakshman A. Modi M. Prakash G. Malhotra P. Khadwal A. Jain S. Kumari S. Varma N. Varma S. Evaluation of bortezomib-induced neuropathy using total neuropathy score (reduced and clinical versions) and NCI CTCAE v4.0 in newly diagnosed patients with multiple myeloma receiving bortezomib-based induction. Clin. Lymphoma Myeloma Leuk. 2017 17 8 513 519.e1 10.1016/j.clml.2017.06.035 28842138
    [Google Scholar]
  39. Lee S.E. Choi K. Han S. Lee J. Hong T. Park G.J. Yim D.S. Min C.K. Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy. Anticancer Drugs 2017 28 6 660 668 10.1097/CAD.0000000000000506 28430745
    [Google Scholar]
  40. Thawani S.P. Tanji K. De Sousa E.A. Weimer L.H. Brannagan T.H. III Bortezomib-associated demyelinating neuropathy--clinical and pathologic features. J. Clin. Neuromuscul. Dis. 2015 16 4 202 209 10.1097/CND.0000000000000077 25996966
    [Google Scholar]
  41. Ravaglia S. Corso A. Piccolo G. Lozza A. Alfonsi E. Mangiacavalli S. Varettoni M. Zappasodi P. Moglia A. Lazzarino M. Costa A. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin. Neurophysiol. 2008 119 11 2507 2512 10.1016/j.clinph.2008.08.007 18829381
    [Google Scholar]
  42. Myftiu B. Hundozi Z. Sermaxhaj F. Blyta A. Shala N. Jashari F. Qorraj Bytyqi H. Hyseni E. Kurtishi I. Chemotherapy-induced peripheral neuropathy (CIPN) in patients receiving 4-6 cycles of platinum-based and taxane-based chemotherapy: A prospective, single-center study from kosovo. Med. Sci. Monit. 2022 28 937856 10.12659/MSM.937856 36042691
    [Google Scholar]
  43. Kleckner I.R. Kamen C. Gewandter J.S. Mohile N.A. Heckler C.E. Culakova E. Fung C. Janelsins M.C. Asare M. Lin P.J. Reddy P.S. Giguere J. Berenberg J. Kesler S.R. Mustian K.M. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: A multicenter, randomized controlled trial. Support. Care Cancer 2018 26 4 1019 1028 10.1007/s00520‑017‑4013‑0 29243164
    [Google Scholar]
  44. Tamburin S. Park S.B. Schenone A. Mantovani E. Hamedani M. Alberti P. Yildiz-Kabak V. Kleckner I.R. Kolb N. Mazzucchelli M. McNeish B.L. Argyriou A.A. Cavaletti G. Hoke A. Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: Systematic review and evidence-based recommendations. Crit. Rev. Oncol. Hematol. 2022 171 103575 10.1016/j.critrevonc.2021.103575 34968623
    [Google Scholar]
/content/journals/cn/10.2174/011570159X376896250624070328
Loading
Assessment Value of Electromyography for Bortezomib-Related Peripheral Neuropathy
Bentham Science Publishers ; https://doi.org/10.2174/011570159X376896250624070328
/content/journals/cn/10.2174/011570159X376896250624070328
/content/journals/cn/10.2174/011570159X376896250624070328
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: bortezomib ; nerve conduction abnormalities ; Electromyography ; progression-free survival (PFS) ; peripheral neuropathy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test